Konstantinos G. Baroutis

Konstantinos G. Baroutis

Auto-generated profile, based on publicly available information

Konstantinos G. Baroutis

Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2025 in AJO International
Verified
Journal Article
Open access
KBKonstantinos G. Baroutis
Konstantinos G. Baroutis
GSGustavo Sakuno
Gustavo Sakuno
SHSandra Hoyek
Sandra Hoyek
NPNimesh A. Patel
Nimesh A. Patel
JMJoan Miller
Joan Miller
DVDemetrios G. Vavvas
Demetrios G. Vavvas
To report the retinal findings, cumulative incidence of retinal capillary hemangioblastoma (RCH), retinal detachment (RD) outcomes, and risk factors in a large cohort of von Hippel-Lindau (VHL) patients within a major U.S. Tertiary Care Facility. A retrospective cohort study was conducted between January 2005 and August 2024. VHL patients were identified from Mass General Brigham's Research Patient Data Repository. Manual chart review confirmed those with ophthalmologic examinations. A nested 1:2 matched case-control study compared RD cases with controls (VHL patients with RCH but without RD). Kaplan-Meier analysis estimated cumulative RCH incidence, and conditional logistic regression identified RD risk factors. Patients without RCH were censored at the last follow-up. Among 159 VHL patients, 104 had comprehensive eye examinations with a median follow-up of 7 years [IQR, 2-11]; 95% attended at least one follow-up appointment. The incidence rate of RCH was 2.3 per 100 person-years, calculated from person-time starting at birth and ending at age of first RCH diagnosis (for cases) or last follow-up visit (for non-cases). Eighteen eyes (14 patients, 13% of the cohort; 95% CI, 8%-22%) developed RD, predominantly combined rhegmatogenous/tractional (94%), with 29% bilateral involvement. Notably, no patient without an RCH developed an RD in our cohort. A case-control study found that each additional prior focal treatment significantly lowered the risk of RD (OR = 0.15, 95% CI 0.03-0.63; p = 0.01), while the presence of renal cell carcinoma and pancreatic cysts were associated with increased risk, possibly indicating more advanced systemic disease. All RD cases exhibited proliferative vitreoretinopathy (PVR; Grade C: 89%, Grade B: 11%) at the time of diagnosis. Overall, 12 of 16 eyes (75%) achieved reattachment, 11 of which (69%) required multiple surgeries (median, 2 [IQR, 1-3]), but visual outcomes remained poor (median final logMAR BCVA, 2.3 [IQR, 0.55-2.7], counting fingers). VHL patients face a high lifetime risk of RCH and associated RD. PVR frequently complicates the surgical treatment of RD and yields limited visual recovery, underscoring the need for proactive surveillance and timely therapeutic intervention. The universal presence of PVR in these RD eyes is a novel finding that warrants investigation into a possible, though currently speculative, molecular link to pVHL dysregulation.

29 July 2026 in Ophthalmology Retina
Verified
Journal Article
Closed access
MBMaria Anna Bantounou
Maria Anna Bantounou
MEMaria Emfietzoglou
Maria Emfietzoglou
TKTiarnán Keenan
Tiarnán Keenan
KBKonstantinos G. Baroutis
Konstantinos G. Baroutis
JMJoan Miller
Joan Miller
DVDemetrios G. Vavvas
Demetrios G. Vavvas

1 July 2026 in BMJ Open Ophthalmology
Verified
Journal Article
Open access
PDF file
MBMaria Anna Bantounou
Maria Anna Bantounou
MEMaria Emfietzoglou
Maria Emfietzoglou
KBKonstantinos G Baroutis
Konstantinos G Baroutis
MSMatthew R Starr
Matthew R Starr
JMJoan W Miller
Joan W Miller
DVDemetrios G. Vavvas
Demetrios G. Vavvas
Objective: Proton-pump inhibitors (PPIs) may disrupt lysosomal acidification, a pathway implicated in age-related macular degeneration (AMD) pathogenesis. We evaluated whether sustained PPI exposure increased the risk of incident AMD in older adults aged ≥60 years. Methods and analysis: This retrospective observational cohort study included adults aged ≥60 years with sustained PPI exposure, matched 1:1 to unexposed controls on demographics, overall health, healthcare utilisation, cardiometabolic factors. Participants were identified from electronic health records. Sustained PPI exposure was defined as ≥2 years of cumulative use within 3 years of the first prescription. Fine-Gray models treating death as a competing event estimated subdistribution hazard ratios (sHRs) for AMD within 10 years; cause-specific Cox models provided complementary HRs. Analyses included histamine H2-receptor antagonists (H2-antagonists) as a negative exposure control and active comparator. Results: Incident AMD occurred in 814/49 796 PPI exposed participants (1.64%) and 668/49 796 controls (1.34%) (overall sHR=1.24, 95% CI 1.12 to 1.38; p<0.001; HR=1.25, 95% CI 1.13 to 1.38, p<0.001). Proportional sHRs were non-constant; sHRs were 1.09 (95% CI 0.91 to 1.29) before 2.5 years and 1.33 (95% CI 1.17 to 1.51) thereafter. For non-exudative AMD, 640 PPI exposed (1.29%) and 510 unexposed (1.02%) participants developed disease (overall sHR=1.28, 95% CI 1.14 to 1.44; p<0.001, HR=1.29, 95% CI 1.14 to 1.44, p<0.001). Among those with non-exudative AMD, 190/2503 PPI-exposed participants (7.59%) and 179/2503 controls (7.15%) progressed to exudative AMD (sHR and HR=1.03, 95% CI 0.84 to 1.26; p=0.802 and p=0.801, respectively). No association was observed between H2-antagonists and AMD (sHR=1.02, 95% CI 0.88 to 1.19; p=0.784; HR=1.03, 95% CI 0.88 to 1.20, p=0.729). Results were consistent in the active-comparator analysis (reciprocal overall sHR=1.24, 95% CI 1.04 to 1.48; p=0.016; HR=1.25, 95% CI 1.05 to 1.49, p=0.012). Conclusion: Sustained PPI exposure was associated with a modestly higher AMD risk, whereas no association was observed with H2-antagonists. The consistency of the active-comparator findings supports the potential specificity of this association and warrants further investigation to determine its clinical implications.

21 September 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KBKonstantinos G. Baroutis
Konstantinos G. Baroutis
VCVictor San Martin C. Corrêa
Victor San Martin C. Corrêa
DNDimitrios Ntentakis
Dimitrios Ntentakis
TNToshio Narimatsu
Toshio Narimatsu
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas
DVDemetrios G. Vavvas
Demetrios G. Vavvas
Verteporfin (VP) is widely used as a light-independent pharmacologic inhibitor of the YAP-TEAD transcriptional complex, despite its potent photosensitizing properties. Here we show that VP-associated high–molecular–weight complexes and apparent depletion of key proteins on immunoblots can be substantially driven by ambient-light exposure during post-lysis handling, more than by light during cellular treatment. In this study, the hypothesis is tested independently using MEL270, HEK293, and MCF-7 cells treated with therapeutic and supra-therapeutic concentrations of VP under four systematically varied light/dark conditions. The results demonstrate that high-molecular-weight complex (HMWC) formation for p62, DIAP1, ROCK1, YAP, and phospho-YAP is driven principally by light exposure during sample processing rather than during cell treatment, occurs in cell-free lysates within 1 hour of ambient-light exposure, and is markedly attenuated by both N-acetylcysteine and L-histidine, consistent with contributions from both radical-mediated and singlet oxygen-mediated photochemistry. Notably, YAP and phospho-YAP are highly susceptible to photo-cross-linking, whereas transcription enhancer factor 1 (TEF1)/TEAD1 remains comparatively resistant, a pattern that mimics selective YAP-TEAD inhibition on standard immunoblots. In a single-experiment CCK-8 assay, viability was markedly lower under light than in darkness at 24 hours, an observation consistent with the immunoblot findings but requiring independent replication. These findings support the light-artifact hypothesis and may have implications for how preclinical data on VP are interpreted in the design of clinical investigations.

11 September 2025 in Eye
Verified
Journal Article
Closed access
PDF file
KBKonstantinos G. Baroutis
Konstantinos G. Baroutis
SHSandra Hoyek
Sandra Hoyek
VCVictor S. M. C. Correa
Victor S. M. C. Correa
DNDimitrios P. Ntentakis
Dimitrios P. Ntentakis
NPNimesh A. Patel
Nimesh A. Patel
DVDemetrios G. Vavvas
Demetrios G. Vavvas

22 June 2026 in Eye
Verified
Journal Article
Closed access
MBMaria Anna Bantounou
Maria Anna Bantounou
DFDimitra Foteinou
Dimitra Foteinou
MEMaria Emfietzoglou
Maria Emfietzoglou
KBKonstantinos G. Baroutis
Konstantinos G. Baroutis
BHBlake M. Hauser
Blake M. Hauser
DVDemetrios G. Vavvas
Demetrios G. Vavvas